Medical News

RSS

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Fiscal 2009 results announced by Opsens

Opsens Inc. today released its results for the year ended August, 31, 2009.

18 Nov 2009

Ionian Technologies receives supplemental funding from the Gates Foundation

Ionian Technologies, Inc., will continue its efforts to develop a rapid point-of-care diagnostics platform for use in the developing world with supplemental funding from the Bill & Melinda Gates Foundation. This grant from the Foundation will extend the total commitment to this program, which was initiated in November 2008, to $3 million over two years.

18 Nov 2009

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.

18 Nov 2009

W. L. Gore to distribute QXMédical's Q50 Stent Graft Balloon Catheter

W. L. Gore & Associates today announced it has entered into a partnership with QXMédical, LLC, a medical device development and marketing company. As part of the agreement, Gore will distribute the Q50 Stent Graft Balloon Catheter which is designed for use with aortic stent grafts that treat abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA).

18 Nov 2009

Unibased Systems Architecture and DST Technologies form a strategic relationship

Unibased Systems Architecture, Inc., a resource, scheduling, and OR management system provider, and DST Technologies, Inc., a process automation and work management solution provider, today announced they have formed a strategic relationship for the purpose of jointly marketing their solutions to better serve clients in the healthcare industry.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

House Medicare 'doc fix' vote likely Thursday amidst disputes about cost, role in health reform

"On Thursday, the House is expected to pass a $210 billion measure — known as the 'doc fix' — that will adjust Medicare payment rates to avoid a 21 percent cut in January and continuing cuts in the years ahead," The New York Times reports, adding: "The House originally included the provision in its big health care bill. But it was dropped because its steep cost would have meant the bill would add to future federal deficits, violating one of President Obama's central requirements for the health legislation."

18 Nov 2009

Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on Power3 Medical Products, the developer of several blood tests designed for early detection, monitoring and targeting of diseases like Alzheimer's, Parkinson's and breast cancer.

18 Nov 2009

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA.

18 Nov 2009

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.

18 Nov 2009

Shamir Optical Industry discloses unaudited financial results for third-quarter 2009

Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the third quarter ended September 30, 2009.

18 Nov 2009

Gene-diet interaction influencing BMI and obesity replicated in three independent studies

Tufts University researchers have identified a gene-diet interaction that appears to influence body weight and have replicated their findings in three independent studies. Men and women carrying the CC genotype demonstrated higher body mass index (BMI) scores and a higher incidence of obesity, but only if they consumed a diet high in saturated fat. These associations were seen in the apolipoprotein A-II gene (APOA2) promoter.

18 Nov 2009

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

IBM ( IBM) announced today that its Research scientists are working with the Rizzoli Orthopedic Institute, in Bologna, Italy, to use information technology to better address treatment and research for rare genetic skeletal diseases.

18 Nov 2009

Medworxx Policy & Procedure Management System implemented at Premier Health Partners

Medworxx Inc., provider of healthcare solutions for patient flow, compliance and education, is pleased to announce that Premier Health Partners has implemented the Medworxx Policy & Procedure Management System.

18 Nov 2009

Way to capture tumor cells in the bloodstream discovered

A team led by University of Arkansas for Medical Sciences (UAMS) researchers on the cutting edge of nanotechnology has found a way to capture tumor cells in the bloodstream that could dramatically improve earlier cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research.

18 Nov 2009

Medical News

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Fiscal 2009 results announced by Opsens

Ionian Technologies receives supplemental funding from the Gates Foundation

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

W. L. Gore to distribute QXMédical's Q50 Stent Graft Balloon Catheter

Unibased Systems Architecture and DST Technologies form a strategic relationship

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

House Medicare 'doc fix' vote likely Thursday amidst disputes about cost, role in health reform

Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Shamir Optical Industry discloses unaudited financial results for third-quarter 2009

Gene-diet interaction influencing BMI and obesity replicated in three independent studies

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

Medworxx Policy & Procedure Management System implemented at Premier Health Partners

Way to capture tumor cells in the bloodstream discovered

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News